anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Steroid-induced osteonecrosis of the femoral head (SONFH), caused by glucocorticoid (GC) administration, is known to exhibit a high incidence worldwide. Although osteoblast apoptosis has been reported as an important cytological basis of SONFH, the precise mechanism remains elusive. Echinacoside (Ech), a natural phenylethanoid glycoside, exerts multiple beneficial effects, such as facilitation of cell proliferation and anti-inflammatory and anticancer activities. Herein, we aimed to explore the regulatory mechanism underlying glucocorticoid-induced osteoblast apoptosis and determine the protective efficacy of Ech against SONFH. We comprehensively surveyed multiple public databases to identify SONFH-related genes. Using bioinformatics analysis, we identified that the PI3K/AKT/FOXO1 signaling pathway was most strongly associated with SONFH. We examined the protective effect of Ech against SONFH using in vivo and in vitro experiments. Specifically, dexamethasone (Dex) decreased p-PI3K and p-AKT levels, which were reversed following Ech addition. Validation of the PI3K inhibitor (LY294002) and molecular docking of Ech and PI3K/AKT further indicated that Ech could directly enhance PI3K/AKT activity to alleviate Dex-induced inhibition. Interestingly, Dex upregulated the expression of FOXO1, Bax, cleaved-caspase-9, and cleaved-caspase-3 and enhanced MC3T3-E1 apoptosis; application of Ech and siRNA-FOXO1 reversed these effects. In vitro, Ech decreased the number of empty osteocytic lacunae, reduced TUNEL and FOXO1 positive cells, and improved bone microarchitecture. Our results provide robust evidence that PI3K/AKT/FOXO1 plays a crucial role in the development of SONFH. Moreover, Ech may be a promising candidate drug for the treatment of SONFH.
Patients undergo radiation therapy 5 days per week for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive lomustine PO on day 1 and temozolomide PO QD on days 2-6. Treatment repeats every 42 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
Participants will receive oral labetalol for blood pressure control. Dosage may initially start at one 200mg tablet by mouth two times per 12 hours (total of 400mg every a day), however dosage may be increased by 100-200mg increments at a time. Maximum dosage for oral labetalol will be 2400mg per day.
Both groups receive amoxicillin/clavulanic acid 1.2 g intravenously every eight hours from admission up to 24 hours postoperatively. Group 2 receives oral placebo using the same schedule for the same duration as group 1.
Early aseptic loosening is caused by deficient osteointegration of the femoral stem due to increased micromotions and represents a common mode of failure in uncemented total hip arthroplasty (THA). This study hypothesized that a higher femoral offset, a smaller stem size and obesity increase femoral micromotion, potentially resulting in early aseptic loosening. A finite element analysis was conducted based on computed tomography segmented model of four patients who received a THA with a triple-tapered straight stem (Size 1, 3, 6). The influence of femoral stem offset (short neck, standard, lateral), head length (S to XXL), femoral anteversion and obesity during daily activities of fast walking and stair climbing was analyzed. The micromotions for the femoral stem zones were compared to a threshold representing a value above which only partial osseointegration is expected. The minimum femoral offset configuration compared to the maximum offset configuration (short neck stem, S head vs. lateral stem, XXL head) leads to a relative mean micromotion increase of 24% for the upper stem zone. Increasing the body weight (body mass index 30-35 kg/m2) increases the micromotion by 20% for all stem zones. The obese population recorded threshold-exceeding micromotions for stem sizes 1 and 3 for all offset configurations during stair climbing. Higher femoral offset, a smaller stem size, and higher loading due to obesity lead to an increase in micromotion between the prosthesis and proximal femur and represent a risk configuration for impaired osseointegration of a triple-tapered straight stem, especially when these three factors are present simultaneously.
NEW MATERIAL:A compound shown by the formula I (R1 is methyl, ethyl, or isopropyl; R2 amino acid residue which may be protected) and its salt. EXAMPLE:5-O-[N-(2,2,2-Trichloroethoxycarbonyl)glycyl]mylbemycin D. USE:An acaricide. An insecticide. An insect repellent. Having improved activity against sanitary insect pests such as acarids, flies, fleas, cockroaches, etc., nematodes, parasites living in animals and human, etc. PREPARATION:A compound shown by the formula II is directly reacted with an amino acid in the presence of a condensation agent such as dicyclohexylcarbodiimide, etc. in an inert solvent at -10 deg.C - room temperature, to give a compound shown by the formula I .
BACKGROUND: Acute compartment syndrome(ACS) is a perilous consequence of trauma. Acute compartment syndrome's precise cause is yet unknown. We performed studies to confirm that acute compartment syndrome can be relieved by suppressing ferroptosis and activating the Nrf2/Hmox1 pathway.
METHODS: We generated an ACS rat model and we conducted next-generation sequencing(NGS) of skeletal muscle tissue and identified differentially expressed target genes. Ultimately, we performed in vivo experiments to validate the presence of ferroptosis and the Nrf2/Hmox1 pathway in ACS rats. After the minocycline intervention, the drug was evaluated for its effects on ACS by examining changes associated with ferroptosis.
RESULTS: The bioinformatics analysis identified that the genetic changes in the disease were mostly focused on ferroptosis, with noticeable modifications in Nrf2/Hmox1. Based on the in vivo results, it was observed that ACS rats exhibited significantly elevated levels of ferroptosis compared to the control rats. The suppression of the Nrf2/Hmox1 pathway mediated by minocycline improves outcomes in ACS and reduces tissue damage after intervention.
CONCLUSION: Minocycline hinders ferroptosis via stimulating the Nrf2/Hmox1 pathway, which slows down the advancement of acute compartment syndrome.
The present invention provides a method of eliciting an enhanced immune response in a subject against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using three incremental doses of a vaccine. The first dose is administered in an amount of 10% to 25% of the full intensity dose of the vaccine. The second dose is used in an amount of 45% to 55% of the full intensity dose of the vaccine 3 to 21 days after the first dose. The final dose is administered in an amount of 100% of the full intensity dose of the vaccine 3 to 21 days after the second dose. The vaccine regimen of the present invention induces an immune response that is as strong or stronger, and/or lasts as long or longer than a vaccine regimen comprising two or three full-strength doses of the vaccine. In one embodiment, the vaccine is an inactivated viral vaccine. In one embodiment, the vaccine is an mRNA vaccine.
BACKGROUND: This study aims to describe post-chikungunya complications chronically developed cases in returning travelers from some epidemic/endemic regions, and the variables that are associated with the progression of acute or subacute cases to the chronic phase.
METHODS: This single-center retrospective cohort study included chikungunya fever cases treated at La Paz-Carlos III University Hospital in Madrid, Spain, April 2014 to September 2016, when the chikungunya outbreak in Latin America started through the time of its greatest impact.
RESULTS: The analysis included 119 cases. Of these, 67.2 % were male, with a median age of 41.0 years [IQR 16.0 to 76.0] years. Only 25.6 % of the patients attended a pre-travel advice consultation. Most patients reported arthralgias, which significantly impacted their daily quality of life (86 %). The mean duration of joint symptoms was 129.4 days, with a median of 90 days [IQR 0 to 715]. Factors found to be associated with chronic arthralgia include female sex, country of infection, age at diagnosis, previous diseases, symptoms during the acute phase, pain in previously injured tendons/joints, acute phase severity, and various laboratory markers such as hemoglobin, hematocrit, total serum bilirubin, and creatinine. Progression to chronic arthralgia significantly increased the need for changes in daily activity. Furthermore, 42.6 % of patients with chronic arthralgia reported recurrence of symptoms once they felt they had disappeared. Targeted treatment regimens led to significant improvements in these patients.
CONCLUSIONS: The results of this study underscore the need for: (1) comprehensive pre-travel advice; (2) effective management of patients in specialized units, alongside early diagnosis and treatment, to prevent trivialization of these viral infections; and (3) the development of interdisciplinary recommendations to assist physicians in treating patients and enhancing outcomes.
There is no known specific antidote for Bortezomib for injection overdosage. In humans, fatal outcomes following the administration of more than twice the recommended therapeutic dose have been reported, which were associated with the acute onset of symptomatic hypotension (5.2) and thrombocytopenia (5.7). In the event of an overdosage, the patient's vital signs should be monitored and appropriate supportive care given. 

Studies in monkeys and dogs showed that intravenous bortezomib doses as low as two times the recommended clinical dose on a mg/m2 basis were associated with increases in heart rate, decreases in contractility, hypotension, and death. In dog studies, a slight increase in the corrected QT interval was observed at doses resulting in death. In monkeys, doses of 3.0 mg/m2 and greater (approximately twice the recommended clinical dose) resulted in hypotension starting at one hour postadministration, with progression to death in 12 to 14 hours following drug administration.
This a randomized prospective study that compares the efficacy and complication rates of early (24 hours) versus late (72 hours) VTE prophylaxis administration to TBI patients. Patients who are identified as having an intracranial injury will be randomized to early versus late VTE prophylaxis using a 1:1 random numbers allocation. Patients in both treatment groups will be monitored for development of VTE, primarily with scheduled duplex ultrasound studies of the lower extremities. Any clinical suspicion of VTE will also be investigated with duplex ultrasound and/or CT angiogram of the chest. Patients will be monitored for development of complications from bleeding post commencement of VTE prophylaxis. Intracranial bleeding complications will be monitored by physical examination and CT scanning of the head when indicated. Patients who undergo craniotomy or craniectomy will have VTE prophylaxis started 72 hours post-surgery and will undergo CT scan of the head (to assure bleeding stabilization) prior to administration of VTE prophylaxis.
Patients receive personalized goal setting for daily steps and activity (updated weekly) and 3 dietary goals (updated monthly) with social media peer support for 6 months. Patients with poor response at 3 months are randomized to Arms 1 or 4. Patients may receive personalized goal setting for daily steps and activity (updated monthly) and dietary goals (updated every 2 months) after 12 months.
Type 2 diabetes is a chronic disease of glucose metabolism leading to various disabling conditions. The onset of type 2 diabetes is a gradual shift from normal to abnormal, giving rarely noticeable symptoms at its early stages or even in later stages when damage has already been caused. Due to the gradual onset, the diagnosis is often delayed, and as much as half of the asymptomatic patients remain undetected. The diagnostic criteria for diabetes are based on artificial boundaries reflecting the risk of complications related to diabetes. The golden standard of diagnosis of diabetes is a 2 hours oral glucose tolerance test, which is both time consuming and costly. This study aims at improving the prediction of type 2 diabetes among high-risk individuals by examining glucose excursion patterns in subjects with impaired glucose tolerance. In addition, this study will show whether the currently used diagnostic test could be replaced by an easier and less expensive method.
Novel alpha-glycosylated soybean glycosides wherein one or more glucosyl residues are bound to the soybean glycoside moiety are prepared. Alpha-glycosylation can be enzymatically achieved by subjecting an aqueous solution containing a soybean glycoside, e.g. soyasaponin or isoflavonoid, and an alpha-glucosyl saccharide to an alpha-glucosyl transferase. Suitable alpha-glucosyl saccharides are liquefied starch, partially hydrolyzed starch and sucrose. Alpha-glucosidase, alpha-amylase, cyclodextrin glucanotransferase, dextransucrase, dextran dextrinase and amylosucrase are usable as the alpha-glucosyl transferase. Since in the alpha-glycosylated soybean glycosides the undesirable bitter, astringent, harsh and lingering choky tastes which are common in intact soybean glycosides are reduced or even eliminated by the alpha-glycosylation, they are suitable for use in food products or orally-usable products wherein taste is an important factor.
<P>PROBLEM TO BE SOLVED: To provide drugs for preventing and treating neurocyte cell injury caused after transient ischemia.  <P>SOLUTION: There are provided drugs for treating or preventing cell injury caused by ischemia which contain, as the active ingredient, midkine family proteins; and drugs for treating or preventing ischemic diseases which contain, as the active ingredient, midkine family proteins. It has been clarified that midkine is efficacious in treating or preventing ischemic diseases and treating or preventing cell injury caused by ischemia and that it can remarkably prevent, for example, the onset of brain infarction which is a typical example of ischemic brain diseases. These remedies and preventives are efficacious against ischemic brain diseases such as brain infarction, transient cerebral ischemia and head injury. In addition, they are efficacious in treating and preventing, for example, cerebrovascular contraction following subarachnoid bleeding, Alzheimer's disease, senile dementia of Alzheimer's type, cerebrovascular dementia and other cerebrovascular diseases, Parkinson's disease, Huntington's chorea and degenerative amyotrophic diseases.  <P>COPYRIGHT: (C)2011,JPO&INPIT
Culturally specific cognitive behavioral therapy. Group format, 8 sessions, approximately 90 minutes. Up to 8-weeks of transdermal nicotine patches. Focused on African Americans: smoking patterns, health outcomes, discrimination, stress, weight concerns, cultural beliefs and practices.
A service of analyzing a homo gene is offered in the form conforming to the requirement of the customer. A service of carrying out gene analysis required by the customer through an electronic request method. A gene info rmation access center is set up, where the gene and its analysis information of the customer is stored. The gene is analyzed in response to the request of the customer and the result is provided. Information meeting the needs of the customer from among a huge amount of information on genome genes is provided with time and in phase. <IMAGE>
The invention belongs to the technical field of medicines, and particularly relates to a steroid compound with tyrosinase inhibitory activity prepared from sophora japonica, a preparation method thereof and application of the compound in treating melanoma. Compounds 1 (isocyathisterol) and 2 (7α -methoxy-5α,6α -epoxyergosta-8 (14), 22-diene-3β -triol) have the structural formulas shown in the following 1 and 2. The compound obtained by the invention is separated from the locust ear for the first time, provides a novel method for preparing the compound, and has the advantages of simple method and higher purity. The invention discovers that the compound has better anti-tyrosinase activity for the first time. Wherein, the IC  50  of the compound 1 to tyrosinase is 25.46+/-3.86 mu M, the IC  50  of the compound 2 to tyrosinase is 31.58+/-4.65 mu M, and the activity of the compound is better than that of the positive drug arbutin (IC  50  is 58.17+/-6.09 mu M). The compounds 1 and 2 can be used as lead compounds for resisting melanoma, and provide scientific basis and new thought for treating the diseases.
Metastatic renal cell carcinoma (RCC) can present with oligometastatic disease and/or develop oligoprogression following systemic therapy. Cytoreductive and focal metastasis-directed therapy options include resection, stereotactic ablative radiation and thermal ablation. Aggressive focal therapy may allow delay in initiation of or modification to systemic therapy and improve clinical outcomes. In this narrative review we synthesize current practice guidelines and prospective data on focal therapy management options and highlight future research. Patient selection and the choice of focal treatment techniques are controversial due to limited and heterogeneous data and patients may benefit from multidisciplinary evaluation. Prospective comparative trials with clearly defined inclusion criteria and relevant end points are needed to clarify the risks and benefits of different approaches.
Schizophrenia (SCZ), which affects approximately 1% of the world's population, is a global public health concern. It is generally considered that the interplay between genes and the environment is important in the onset and/or development of SCZ. Although several whole-exome sequencing studies have revealed rare risk variants of SCZ, no rare coding variants have been strongly replicated. Assessing isolated populations under extreme conditions might lead to the discovery of variants with a recent origin, which are more likely to have a higher frequency than chance to reflect gene-environment interactions. Following this approach, we examined a unique cohort of Tibetans living at an average altitude above 4500 meters. Whole-exome sequencing of 47 SCZ cases and 53 controls revealed 275 potential novel risk variants and two known variants (12:46244485: A/G and 22:18905934: A/G) associated with SCZ that were found in existing databases. Only one gene (C5orf42) in the gene-based statistics surpassed the exome-wide significance in the cohort. Metascape enrichment analysis suggested that novel risk genes were strongly enriched in pathways relevant to hypoxia, neurodevelopment, and neurotransmission. Additionally, 47 new risk genes were followed up in Han sample of 279 patients with SCZ and 95 controls, only BAI2 variant appearing in one case. Our findings suggest that SCZ patients living at high altitudes may have a unique risk gene signature, which may provide additional information on the underlying biology of SCZ, which can be exploited to identify individuals at greater risk of exposure to hypoxia.
The "Antisalmin" biological product introduces microflora in the intestinal tract which is useful for the organism of the hatched chicks thus preventing its habitation by salmonella and the pathogenous Esch. coli. It contains specific microorganisms isolated by the intestinal tract of healthy chicks grown under home conditions. The bacterial inhabiting the intestinal tract also synthetize antimicrobial substances against the salmonella and pathogenous Esch. coli. The product is administered in the first drinking water given to the chicks immediately after their hatching or is pulverized on the eggs when 50% of the chicks are hatched.
A cosmetic base containing a solid, lipophilic filter for UV-A and/or UV-B and a solubilising agent selected from isoamyl-p-methoxycinnamate (I), 2-ethylhexyl-p-methoxycinnamate (II) or mixtures of these.  The cosmetic base is preferably in the form of an oil-in-water or water-in-oil emulsion. The lipophilic solid filter for UV-A and/or UV-B is present in an amount of 0.5-10 wt. % on total weight of the composition. The solubilising agent (I) or (II) is present in an amount of 0.5-30 (1-10) wt. % on total weight of the composition. The composition may additionally contain at least one second filter compound for UV-A and/or UV-B selected from hydrophilic or lipophilic organic compounds such as salicylic derivatives, camphor derivatives, triazine derivatives, benzophenone derivatives, dibenzoylmethane derivatives,  beta , beta -diphenylacrylate derivatives, p-aminobenzoic acid derivatives or mixtures of these. The composition may additionally contain at least one complementary photoprotective agent selected from optionally coated metal oxide pigments and nanopigments capable of physically blocking UV radiation by diffusion and/or reflection. Suitable pigments and nanopigments are based on oxides of Ti, Zn, Fe, Zr or Ce or mixtures of these oxides. The composition may additionally contain agents for artificial browning or bronzing of the skin; fatty substances; organic solvents; ionic or nonionic thickeners; softeners; antioxidants; opacifiers; stabilisers; emollients; silicones;  alpha -hydroxyacids; antifoaming agents; moisturisers; vitamins; perfumes; preservatives; surfactants; fillers; sequestering agents; polymers; propellants; alkalising or acidifying agents; and/or colourants.
PURPOSE: Generalized muscle weakness is the primary characteristic of sarcopenia. Handgrip strength (HGS) is widely employed to detect muscle weakness. However, knee extension strength (KES) declines much earlier and more pronounced than HGS, and there is a stronger correlation between KES and functional performance. Therefore, KES may be a more appropriate proxy for identifying muscle weakness compared to HGS. The purpose of this review was to clarify the KES measurement towards a standardized approach and summarize the cut-off points for KES.
METHODS: A literature search was conducted in Web of Science, PubMed, Elsevier, Scopus and Medline databased up to July 10th, 2023.
RESULTS: A total of 12 articles were ultimately included in this review, which proposed various cut-off points for KES. Notably, these studies exhibited high heterogeneities, including diverse living settings for participants, KES measurement, methods for KES normalization, methodologies for determining cut-off points and study designs.
CONCLUSIONS: No consensus on cut-off points for KES was reached due to the heterogeneities in KES measurement and normalized methods among studies. To enhance the comparability among studies and facilitate the sarcopenia screening framework, a standardized approach for KES measurement and KES normalization are needed. Regarding KES measurement, the hand-held dynamometer-based isometric KES is easy to access and ideally suited for both clinical and community settings, while isokinetic KES, representing the gold standard, is preferred for research settings. Additionally, it is suggested to normalize isometric KES to body weight (BW), while normalizing isokinetic KES to allometrically scaled BW.